Stock & Company Details
Royalty Pharma plc $RPRX
Price:
N/A
N/A
445M
$25B
52 Week High:
N/A
10 Day Average Volume:
N/A
38.49
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
RPRX technical indicators
Latest Royalty Pharma plc (RPRX) indicator readings as of 2026-10-09.
RPRX's 14-day RSI is 40.3, in neutral territory. At $56.93 it is trading 10.5% above its 200-day moving average of $51.52, and below its 50-day average of $59.16. Price sits in the middle of its Bollinger Bands ($56.18 to $59.54). ADX reads 33.7, indicating a trending market.
RPRX backtested strategy results
How 4 rule-based strategies performed on Royalty Pharma plc (RPRX) over recent history, last backtested 2026-09-08. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +39.2% | 57% | 7 | -29.2% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +2.5% | 26% | 27 | -53.1% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -23.9% | 29% | 28 | -42.4% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +33.4% | 80% | 15 | -17.2% |
Overview
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Finance Bot
Ask your questions
Start by typing a question below.
